Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737237 | 0.84 | TP53 (0.45) | MAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL19375437 | 0.83 | TSHR (0.53) | BCHECYP4F2CYP4A11MAOBNR4A2 | |
| SCHEMBL10289884 | 0.83 | KDM4E (0.53) | BCHEMAOBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2368219 | 0.83 | MAOB (0.43) | BCHECYP4F2CYP4A11MAOBKCNH2 | |
| SCHEMBL4121634 | 0.83 | MAOB (0.49) | MAOBTAAR1 | |
| SCHEMBL5666508 | 0.83 | BCHE (0.40) | BCHECYP4F2CYP4A11MAOBKCNH2 | |
| Hydrochloric Acid SCHEMBL25370652 | 0.82 | MAOB (0.50) | MAOBKCNH2TAAR1 | |
| Hydrochloric Acid SCHEMBL31173733 | 0.82 | MAOB (0.50) | MAOBKCNH2TAAR1 | |
| SCHEMBL3663796 | 0.80 | CYP4F2 (0.45) | BCHECYP4F2CYP4A11MAOBKCNH2 | |
| SCHEMBL15561594 | 0.80 | MAOB (0.40) | BCHECYP4F2CYP4A11MAOBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-1465880-B1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE | IPSEN PHARMA (FR) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | BCHE 72/4885CYP4F2 3888/4885CYP4A11 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.